Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial.

"Competing interests: TT has received consulting fees from Taiho, AbbVie, Gilead, Mitsubishi-Tanabe, Chugai and Eli Lilly; has received research grants from AbbVie, Chugai, Eisai, Mitsubishi-Tanabe, ONO and AYUMI; has received honoraria from AbbVie, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Mitsubishi-Tanabe, Pfizer and Janssen. ST has received consulting fees from Taiho, Mitsubishi-Tanabe, Gilead, Chugai, AbbVie, Astellas and Eli Lilly; has conducted joint research with Eli Lilly; has received honoraria for lectures and presentations from Mitsubishi-Tanabe, Pfizer, ONO, Bristol-Myers Squibb, Gilead, Eisai, Chugai, AbbVie, Astellas and Eli Lilly; has received travel fees from Mitsubishi-Tanabe, Pfizer, ONO, Bristol-Myers Squibb, Gilead, Eisai, Chugai, AbbVie, Astellas and Eli Lilly; serves as a board member for the Japan College of Rheumatology, the Japanese Society for Clinical Rheumatology and Related Research, the Japan Society for Rheumatism and Joint Surgery and the Japan Rheumatism Foundation. MM has received consulting fees from Taiho; and serves as a executive director of the Japanese Society of Thrombosis and Hemostasis. YT has received consulting fees from Taiho; has received speaker’s fees and/or honoraria from Boehringer-Ingelheim, Eli Lilly, AbbVie, Gilead, AstraZeneca, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Pfizer, Mitsubishi-Tanabe and GlaxoSmithKline; and has received research grants from Asahi-Kasei, AbbVie, Chugai, Eisai, Takeda, Daiichi Sankyo, Boehringer-Ingelheim and Asahi-Kasei."

"Funding: The study was sponsored by Taiho."

"Trial registration numbers NCT03605251, JapicCTI-184020, jRCT2080223962."